Koneksa, a NYC-based developer of patient-centric digital biomarkers for drug development, closed a $16M Series B financing round.
The round was led by Spring Mountain Capital with participation from McKesson Ventures, Novartis Pharma AG and MBX Capital and existing investors Merck Global Health Innovation Fund and Waterline Ventures.
The company plans to use the investment to expand their investment in internal R&D to develop and validate digital endpoints, advance the capabilities of the digital biomarker platform, establish strategic partnerships, and expand its geographical footprint.
Launched in 2015 and led by Chris Benko, CEO, Koneksa develops its digital platform for integrating wearables, sensors, and other patient-facing technologies into clinical research. The company has partnered with pharmaceutical and biotech companies to develop and implement digital biomarkers that support clinical development programs across therapeutic areas including neuroscience, respiratory, rare diseases, and oncology.
The company offers a solution based on its SaaS platform and mobile application that facilitate the capture, monitoring, and analysis of patient-generated data collected at home and remotely. Koneksa’s own mobile assessments and the ability to work with a variety of existing wearable sensors allow for a broad array of data inputs.